Market Overview

EC Approves Ironwood's Constella for Treatment of Irritable Bowel Syndrome with Constipation in Adults


Almirall and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the European Commission has granted marketing
authorization to Constella® (linaclotide 290mcg) for the
symptomatic treatment of moderate to severe Irritable Bowel Syndrome
with Constipation (IBS-C) in adults. This approval follows the positive
recommendation received from the European Committee for Medicinal
Products for Human Use (CHMP) in September.

Constella® is an oral, once-daily medication. Linaclotide,
the active ingredient in Constella®, is a guanylate cyclase-C
agonist (GCCA) with visceral analgesic and secretory activities, as
stated in the product label for European use. In non-clinical studies,
linaclotide has been shown to reduce visceral pain by decreasing
pain-fiber activity and to accelerate gastrointestinal transit

See full press release

Posted-In: News Guidance M&A Global


Related Articles (IRWD)

View Comments and Join the Discussion!